LeMaitre Vascular Appoints New Director, Officer Comp Details
Ticker: LMAT · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1158895
| Field | Detail |
|---|---|
| Company | Lemaitre Vascular Inc (LMAT) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $565,000, $225,000, $375,000, $100,000, $120,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, director-appointment, director-departure
Related Tickers: LMAT
TL;DR
LeMaitre Vascular board shakeup: D'Amato out, Astion in. Officer pay details also filed.
AI Summary
On February 7, 2025, LeMaitre Vascular, Inc. filed an 8-K report detailing the departure of Director David M. D’Amato and the appointment of Dr. David E. Astion as a new director. The filing also disclosed compensatory arrangements for certain officers, though specific details of these arrangements were not provided in the excerpt.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns board changes and standard disclosures, with no immediate financial or operational risks indicated.
Key Players & Entities
- LeMaitre Vascular, Inc. (company) — Registrant
- David M. D’Amato (person) — Departing Director
- Dr. David E. Astion (person) — Appointed Director
- 001-33092 (company) — SEC File Number
- February 7, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as a new director to the LeMaitre Vascular board?
Dr. David E. Astion has been appointed as a new director.
Who has departed from the LeMaitre Vascular board of directors?
David M. D’Amato has departed from the board of directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 7, 2025.
What is the principal executive office address for LeMaitre Vascular, Inc.?
The address is 63 Second Avenue, Burlington, Massachusetts 01803.
What is the SEC file number for LeMaitre Vascular, Inc.?
The SEC file number is 001-33092.
Filing Stats: 891 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2025-02-13 09:00:12
Key Financial Figures
- $565,000 — es for a starting annual base salary of $565,000, a yearly discretionary performance bon
- $225,000 — ormance bonus with the target amount of $225,000, an annual equity award of $375,000 wit
- $375,000 — of $225,000, an annual equity award of $375,000 with four-year vesting, and a one-time
- $100,000 — ard of restricted stock units valued at $100,000 with four-year vesting. Mr. LeBlanc wil
- $120,000 — participant involving amounts exceeding $120,000 and in which Mr. LeBlanc had or will ha
Filing Documents
- lmat20250212_8k.htm (8-K) — 29KB
- ex_777529.htm (EX-10.1) — 23KB
- lemait_logo01.jpg (GRAPHIC) — 13KB
- lemait_logo02.jpg (GRAPHIC) — 22KB
- lemait_logo03.jpg (GRAPHIC) — 15KB
- 0001437749-25-003679.txt ( ) — 256KB
- lmat-20250207.xsd (EX-101.SCH) — 3KB
- lmat-20250207_def.xml (EX-101.DEF) — 11KB
- lmat-20250207_lab.xml (EX-101.LAB) — 15KB
- lmat-20250207_pre.xml (EX-101.PRE) — 11KB
- lmat20250212_8k_htm.xml (XML) — 3KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) Appointment of Dorian LeBlanc as Chief Financial Officer On February 7, 2025, LeMaitre Vascular, Inc. (the "Company") agreed to terms with Dorian LeBlanc to become the Chief Financial Officer and principal financial officer of the Company, effective on March 10, 2025. Mr. LeBlanc, age 50, joins the Company from LumiraDx Limited (recently acquired by Roche), a next-generation point of care diagnostic company, where he most recently served as Chief Financial Officer since November 2016, and was appointed Vice President, Global Operations in August 2020, and subsequently appointed Chief Operating Officer in November 2023. Prior to joining LumiraDx, Mr. LeBlanc held several positions with Alere Inc. from 2007 to 2015, including Vice President of Finance, Infectious Disease Global Business Unit from 2013 to 2015, and Vice President, Finance and Business Development for Asia Pacific from 2012 to 2015. From 2005 to 2007, Mr. LeBlanc served as Vice President, Finance at Camden National Corporation. From 2003 to 2005, Mr. LeBlanc served as controller for Pierce, a company in the Omnicom group. Mr. LeBlanc received a B.A. in economics from Bowdoin College, and an M.S. in accounting and an M.B.A. from Northeastern University. Mr. LeBlanc is a licensed Certified Public Accountant in the State of Maine. In connection with Mr. LeBlanc's appointment as Chief Financial Officer, Mr. LeBlanc and the Company entered into an offer letter (the "LeBlanc Agreement") which provides for a starting annual base salary of $565,000, a yearly discretionary performance bonus with the target amount of $225,000, an annual equity award of $375,000 with four-year vesting, and a one-time award of restricted stock units valued at $100,000 with four-year vesting. Mr. LeBlanc will also be eligible to participate in the Company's sponso
01
Item 9.01. Financial Statement and Exhibits. (d) Exhibits Exhibit Number Description 10.1 LeMaitre Vascular, Inc. Offer Letter to Dorian LeBlanc 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEMAITRE VASCULAR, INC. Dated: February 13, 2025 By: /s/ Joseph P. Pellegrino, Jr. Name: Joseph P. Pellegrino, Jr. Title: Chief Financial Officer and Secretary